SCHEMBL9926817

SCHEMBL9926817

CC(C)[C@H]1COC(=O)N1C

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.56
IL6ST P40189 5/20 0.43
AR P10275 1/20 0.37
STAT3 P40763 1/20 0.37
IDH1 O75874 13/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10049353 1.00 PIK3CD (0.56) PIK3CDIL6STARSTAT3IDH1
SCHEMBL9926814 1.00 PIK3CD (0.56) PIK3CDIL6STARSTAT3IDH1
SCHEMBL21657352 0.81 PIK3CD (0.42) PIK3CDIL6ST
SCHEMBL2033251 0.81 PIK3CD (0.42) PIK3CDIL6ST
SCHEMBL10308941 0.80 PIK3CD (0.42) PIK3CDIL6STIDH1
SCHEMBL1717114 0.79 PIK3CD (0.44) PIK3CDIL6STARSTAT3IDH1
SCHEMBL12706216 0.79 PIK3CD (0.41) PIK3CDIL6ST
SCHEMBL21657351 0.78 PIK3CD (0.40) PIK3CDIL6ST
SCHEMBL10308833 0.77 PIK3CD (0.55) PIK3CDIL6STSTAT3IDH1
SCHEMBL18391318 0.77 PIK3CD (0.55) PIK3CDIL6STSTAT3IDH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3464297-B1 PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF Dr Reddys Laboratories Ltd (IN) 2023-10-25 EP disclosed
US-10836776-B2 Process for preparation of eribulin and intermediates thereof DR. REDDY'S LABORATORIES LIMITED (IN) 2020-11-17 US disclosed
US-20190276470-A1 PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF DR. REDDY'S LABORATORIES LIMITED (IN) 2019-09-12 US disclosed
WO-2017203459-A1 PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF DR. REDDY'S LABORATORIES LIMITED (IN) 2017-11-30 WO disclosed
US-20170204065-A1 PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF ALCON INC. (CH) 2017-07-20 US disclosed
US-20170137384-A1 PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF ALCON INC. (CH) 2017-05-18 US disclosed
US-9624183-B2 Process for the preparation of a fluorolacton derivative GILEAD PHARMASSET LLC (US) 2017-04-18 US disclosed
US-20150315165-A1 PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE HOFFMANN-LA ROCHE INC. (US) 2015-11-05 US disclosed
US-8703963-B2 Derivative N-thiolated 2-oxazolidinone antibiotics UNIVERSITY OF SOUTH FLORIDA (US) 2014-04-22 US disclosed
WO-2013151161-A1 NOVEL COMPOUND, METHOD FOR PRODUCING SAME AND ANTITUMOR AGENT 学校法人東京理科大学 (JP) 2013-10-10 WO disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20120149911-A1 DERIVATIVE N-THIOLATED 2-OXAZOLIDINONE ANTIBIOTICS UNIVERSITY OF SOUTH FLORIDA (US) 2012-06-14 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
US-8017779-B2 Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-09-13 US disclosed
US-8017779-B2 Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-09-13 US disclosed
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-13 US disclosed
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836776-B2 Process for preparation of eribulin and intermediates thereof ERLIN1, ERLIN2, DHPS PIK3CD 1977/4885IL6ST 2497/4885AR 2217/4885
US-20170137384-A1 PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF MAP3K1, MAP3K6, MAP3K7 PIK3CD 103/4885IL6ST 3302/4885AR 4536/4885
US-20070213356-A1 Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines IL2, IFNG, IRF3 PIK3CD 1555/4885IL6ST 24/4885AR 4158/4885
US-20120149911-A1 DERIVATIVE N-THIOLATED 2-OXAZOLIDINONE ANTIBIOTICS TST, NRDC, NUCB2 PIK3CD 4556/4885IL6ST 3917/4885AR 2906/4885
US-20170204065-A1 PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF MAP3K1, MAP3K6, MAP3K7 PIK3CD 103/4885IL6ST 3302/4885AR 4536/4885
US-20150315165-A1 PROCESS FOR THE PREPARATION OF A FLUOROLACTON DERIVATIVE CYP2B6, CYP2F1, CYP3A5 PIK3CD 3266/4885IL6ST 508/4885AR 2940/4885
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 PIK3CD 4654/4885IL6ST 554/4885AR 2260/4885
US-20190276470-A1 PROCESS FOR PREPARATION OF ERIBULIN AND INTERMEDIATES THEREOF ERLIN1, ERLIN2, DHPS PIK3CD 1977/4885IL6ST 2497/4885AR 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.